India  

Covaxin led to tolerable safety outcomes & enhanced immune responses, says Lancet

IndiaTimes Friday, 22 January 2021
Even as a controversy rages over the safety of India’s first indigenous Covid-19 vaccine Covaxin after it was granted Emergency Use Authorisation (EUA) even as Phase III efficacy trials are underway, renowned medical journal Lancet said the vaccine, codenamed BBV152, led to tolerable safety outcomes and enhanced immune responses. “The overall incidence of solicited local and systemic adverse events in this study was 14-21% in all vaccine-treated groups, which is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.”
0
shares
ShareTweetSavePostSend
 

💡 newsR Knowledge: Other News Mentions

BBV152 BBV152 Vaccine against COVID-19

Mexico experts recommend approving Indian vaccine

A technical committee of experts in Mexico gave a unanimous favorable opinion Friday on approving the Covaxin vaccine made by the Indian pharmaceutical company..
IndiaTimes

Govt sees Covaxin efficacy as validation of its scientific process

The phase 3 results of Covaxin released on Wednesday showing 81% efficacy is seen by the government as a major validation of the scientific process and..
IndiaTimes
Covid vaccine explained: Covishield? Covaxin? Do's and Don'ts | Oneindia News [Video]

Covid vaccine explained: Covishield? Covaxin? Do's and Don'ts | Oneindia News

The second phase of India's covid vaccine drive is receiving an enthusiastic response. However, if you are hesitant about the vaccine since you are on medication or recently recovered from some serious illness or even Covid-19 for that matter, you may have some questions that we address in this video. #Covaxin #Covishield #CovidVaccine

Credit: Oneindia    Duration: 03:13Published

Covaxin has 81% interim vaccine efficacy - here's what it means

The trials for the third phase of the vaccine involved 25,800 subjects and it was the largest ever conducted in India.
DNA

Coronavirus disease 2019 Coronavirus disease 2019 Disease caused by severe acute respiratory syndrome coronavirus 2

COVID-19: THESE government employees to be reimbursed for vaccine 'medical expenses'

Government has decided that employees who are insured by United India Insurance Corporation Limited, will be reimbursed the Covid 19 vaccination cost.
DNA
Covid-19 lockdown linked to uptick in tobacco use: Study [Video]

Covid-19 lockdown linked to uptick in tobacco use: Study

A new study has found that pandemic-related anxiety, boredom, and irregular routines were cited as major drivers of increased nicotine and tobacco use during the initial Covid-19 lockdown. The findings of the study were published in the International Journal of Drug Policy. The research was led by Columbia University's Mailman School of Public Health. The study highlighted the ways that public health interventions and policies can better support quit attempts and harm reduction, both during the Covid-19 pandemic and beyond. Decreased use, while less common, was prevalent among "social" tobacco users, who cited fewer interpersonal interactions during the lockdown and a fear of sharing products. At the community level, retail access impacted cigarette and ENDS use differently. While cigarettes were universally accessible in essential businesses, such as convenience stores and gas stations, access to preferred ENDS products was more limited, since "vape shops" and other specialty ENDS retailers were typically deemed non-essential and required to close or limit hours. This drove some ENDS users to order their products online, which often resulted in long wait times due to shipping delays, or product backorder as a result of high demand. As a result, some dual users of cigarettes and ENDS increased their use of readily-available cigarettes.

Credit: ANI    Duration: 01:13Published

You Might Like


Related news from verified sources

Covaxin led to tolerable safety outcomes & enhanced immune responses, says Lancet

Even as a controversy rages over the safety of India’s first indigenous Covid-19 vaccine Covaxin after it was granted Emergency Use Authorisation (EUA) even as...
IndiaTimes

Covaxin effectively neutralises UK variants: Bharat Biotech

India's first indigenous Covid-19 vaccine Covaxin effectively neutralises the deadly and infectious UK variants of SARS-CoV-2 virus, reducing the possibility of...
IndiaTimes